TD Private Client Wealth LLC Grows Stock Holdings in Pfizer Inc. $PFE

Key Points

• TD Private Client Wealth LLC increased its stake in Pfizer Inc. by 19.9%, acquiring an additional 25,456 shares, bringing its total holdings to valued at $3.71 million.
• Pfizer reported quarterly earnings of $0.78 per share, exceeding analysts' expectations and achieving a revenue of $14.65 billion, which is a 10.3% year-over-year increase.
• Analyst ratings for Pfizer are mixed, with a consensus rating of "Hold" and average target price of $28.12, indicating cautious optimism about the stock's performance.

TD Private Client Wealth LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 19.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 153,109 shares of the biopharmaceutical company's stock after acquiring an additional 25,456 shares during the quarter. TD Private Client Wealth LLC's holdings in Pfizer were worth $3,711,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer in the first quarter valued at about $27,000. North Capital Inc. bought a new stake in shares of Pfizer in the 1st quarter valued at about $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer during the first quarter valued at approximately $28,000. Horizon Financial Services LLC bought a new position in Pfizer in the first quarter worth approximately $35,000. Finally, WPG Advisers LLC purchased a new stake in Pfizer during the first quarter worth $35,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 0.3%

PFE stock opened at $24.07 on Thursday. The stock has a market capitalization of $136.82 billion, a PE ratio of 12.80, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average of $24.59 and a 200 day moving average of $24.18.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

PFE has been the subject of several recent research reports. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Berenberg Bank decreased their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Bank of America increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, September 20th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.